Core Viewpoint - InSilico Medicine is pursuing an IPO in Hong Kong after multiple failed attempts, with a significant accumulated loss of $591 million from 2021 to 2024, raising concerns about its long-term viability and business model [1][4][5]. Financial Performance - The company reported revenues of $4.713 million, $30.147 million, $51.18 million, and $85.834 million from 2021 to 2024, respectively, with net losses of $131 million, $222 million, $212 million, and $17.096 million during the same period [5][6]. - The projected revenue for 2024 shows a growth of 92% compared to 2022, with a significant reduction in net loss by 92% [6][7]. Business Model and Operations - InSilico Medicine's core business model focuses on AI-driven drug discovery and pipeline drug development, with 92.9% of its 2024 revenue coming from this segment [7][8]. - The company has 15 candidate drugs in its pipeline, primarily in fibrosis, oncology, and immunology, but has yet to achieve commercialization [7][8]. Funding and Future Plans - The IPO proceeds are intended for further clinical development of key drug candidates, development of new AI models, and operational funding [4][5]. - The company completed a $100 million Series E financing round, increasing its valuation from $894.7 million to $1.3305 billion, reflecting a 48.71% increase over two and a half years [8].